Literature DB >> 15836966

Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors.

Rami Burstein1, Moshe Jakubowski, Dan Levy.   

Abstract

Consistent with previous accounts, some of the patients visiting our pain clinic during the course of a migraine attack have indicated-without solicitation-that sumatriptan injection initially intensified their headache before they were able to appreciate any pain relief. In this study, those patients who came forward complaining about pain exacerbation were asked to rate their headache intensity every 5 min. Within 5-15 min of sumatriptan injection, 17 of the 31 patients studied (55%) reported that their migraine pain intensified for 10-15 min before they started to notice any pain relief. Similar pattern of pain exacerbation was also observed in migraine attacks treated with oral formulation of almotriptan, eletriptan, rizatriptan, and zolmitriptan. To investigate the possible mechanism underlying this transient exacerbation of pain, we examined whether intravenous administration of sumatriptan can alter the response properties of C- and Adelta-meningeal nociceptors in the rat. Five to twenty minutes after intravenous administration of 300 microg/kg sumatriptan, 8/10 C-units and 2/8 Adelta-units increased their firing rate, and 6/10 C-units and 7/8 Adelta-units developed mechanical hyper-responsiveness to dural indentation. The minimal effective dose for activation and sensitization of meningeal nociceptors by sumatriptan was 3 microg/kg, suggesting that relatively low levels of triptans entering the circulation shortly after their administration can alter the physiological properties of meningeal nociceptors and produce a transient exacerbation of headache.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15836966     DOI: 10.1016/j.pain.2005.01.027

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  10 in total

1.  The complex actions of sumatriptan on rat dural afferents.

Authors:  Andrea M Harriott; Nicole N Scheff; Michael S Gold
Journal:  Cephalalgia       Date:  2012-06-18       Impact factor: 6.292

Review 2.  Preclinical neuropharmacology of naratriptan.

Authors:  Geoffrey A Lambert
Journal:  CNS Drug Rev       Date:  2005

Review 3.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 4.  Endogenous mechanisms underlying the activation and sensitization of meningeal nociceptors: the role of immuno-vascular interactions and cortical spreading depression.

Authors:  Dan Levy
Journal:  Curr Pain Headache Rep       Date:  2012-06

Review 5.  Serotonin and migraine: a reconsideration of the central theory.

Authors:  Alessandro Panconesi
Journal:  J Headache Pain       Date:  2008-07-31       Impact factor: 7.277

6.  Headaches related to triptans therapy in patients of migrainous vertigo.

Authors:  Sanjay Prakash; Bhavana V Chavda; Hiren Mandalia; Rishi Dhawan; Deepak Padmanabhan
Journal:  J Headache Pain       Date:  2008-04-22       Impact factor: 7.277

Review 7.  Cutaneous allodynia and migraine: another view.

Authors:  Carl Dahlöf
Journal:  Curr Pain Headache Rep       Date:  2006-06

8.  Episodic dural stimulation in awake rats: a model for recurrent headache.

Authors:  Michael L Oshinsky; Sumittra Gomonchareonsiri
Journal:  Headache       Date:  2007 Jul-Aug       Impact factor: 5.887

Review 9.  Migraine pain: reflections against vasodilatation.

Authors:  Alessandro Panconesi; Maria Letizia Bartolozzi; Leonello Guidi
Journal:  J Headache Pain       Date:  2009-06-05       Impact factor: 7.277

10.  Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache.

Authors:  Hashmat Ghanizada; Mohammad Al-Mahdi Al-Karagholi; Nanna Arngrim; Mette Mørch-Rasmussen; Matias Metcalf-Clausen; Henrik Bo Wiberg Larsson; Faisal Mohammad Amin; Messoud Ashina
Journal:  J Headache Pain       Date:  2020-02-24       Impact factor: 7.277

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.